Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

Somatostatin and Its Receptor Family

1999 • 1,597 citations

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1993 • 1,563 citations

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

2000 • 1,083 citations

Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

1995 • 366 citations

The somatostatin receptor family

1995 • 356 citations

Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy

1999 • 331 citations

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

1994 • 271 citations

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

1999 • 226 citations

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

1997 • 211 citations

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

1998 • 210 citations

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

1997 • 210 citations

Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.

1998 • 136 citations

The somatostatin receptor-targeted radiotherapeutic [ 90 Y-DOTA- d Phe 1 ,Tyr 3 ]octreotide ( 90 Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

1998 • 134 citations

Absorbed fractions for electrons and beta particles in spheres of various sizes.

1994 • 131 citations

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide

1998 • 118 citations

Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.

1999 • 112 citations

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

1999 • 105 citations

Tumour uptake of the radiolabelled somatostatin analogue [DOTA 0 ,TYR 3 ]octreotide is dependent on the peptide amount

1999 • 96 citations

Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.

1996 • 89 citations

Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.

1996 • 86 citations

Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with188Re-RC-160, a directly-radiolabeled somatostatin analogue

1996 • 84 citations

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

1998 • 81 citations

Somatostatin Analogues for Somatostatin-Receptor-Mediated Radiotherapy of Cancer

1996 • 74 citations

Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.

1999 • 73 citations

In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.

2000 • 66 citations

Receptor-mediated Radionuclide Therapy with ⁹⁰Y-DOTA-D-Phe¹-Tyr³-Octreotide: Preliminary Report in Cancer Patients

1999 • 59 citations

Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver

1999 • 53 citations

Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.

1994 • 47 citations

Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats

1997 • 8 citations